Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Crucell, SBL Vaccin AB deal

CRXL acquired SBL for E39.4 million ($50.5 million)

Read the full 86 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE